{"id":"NCT01298141","sponsor":"Shire","briefTitle":"A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease","officialTitle":"A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal® (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-08-10","primaryCompletion":"2017-09-25","completion":"2017-09-25","firstPosted":"2011-02-17","resultsPosted":"2019-02-15","lastUpdate":"2021-06-08"},"enrollment":171,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Fabry Disease"],"interventions":[{"type":"BIOLOGICAL","name":"agalsidase alfa","otherNames":["Replagal"]}],"arms":[{"label":"Replagal®","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to observe the safety of agalsidase alfa in Canadian patients with Fabry disease.","primaryOutcome":{"measure":"Number of Participants With Treatment-emergent Adverse Events (TEAEs)","timeFrame":"From the start of study treatment up to 30 days after the last dose of study drug administration (up to 320 weeks)","effectByArm":[{"arm":"Replagal (Agalsidase Alfa)","deltaMin":163,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":12,"countries":["Canada"]},"refs":{"pmids":["34542871"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":74,"n":167},"commonTop":["Fatigue","Nasopharyngitis","Nausea","Oedema peripheral","Dizziness"]}}